BO45217

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

Study Name:
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

Targeted Disease(s):
Lung Cancer

Purpose of Study:

The purpose of this study is to assess the safety and efficacy of divarasib compared to locally approved KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung cancer (NSCLC). (KRASCENDO-1)

Study Dates:
September 23, 2024 - September 30, 2029

Study Location:
Nationwide

Sponsors:

F. Hoffmann-La Roche Ltd

https://clinicaltrials.gov/study/NCT06497556

Register for Trial
Freedom From Smoking Clinic - Richmond, VA
Richmond, VA | Jan 06, 2025
Freedom From Smoking Clinic - Richmond, VA
Richmond, VA | Mar 10, 2025